Source: Fierce Biotech Jazz Pharmaceuticals has drummed up a deal in double time, agreeing to buy Chimerix for $935 million just days after its CEO voiced an interest in diversifying the pipeline. Buying Chimerix will give Jazz control of the brain cancer drug candidate dordaviprone. The FDA is set to decide whether…...